Rocket Lab Just Had the Worst Week in Its History. Here's What I'd Do With the Stock Now.

Rocket Lab shares fell 23% from Oct. 12 to Oct. 16 after the company pushed the Neutron rocket’s first launch to 2027 because of a carbon-composite tank defect and Ligado challenged its planned $8 billion Iridium acquisition before the FCC. The company reported a $2.36 billion backlog at the end of Q2, but its $30.5 billion market capitalization equates to 32 times this year’s sales, and it is expected to remain unprofitable until 2028. The article says growth depends partly on Neutron’s launch and closing the Iridium deal, and recommends waiting for clearer progress.

Analysis

The key risk is not the launch segment’s current revenue share; it is whether the Neutron delay breaks the credibility of the growth curve embedded in a premium multiple. Repeated schedule slippage can defer customer revenue, raise development-cost risk, and weaken Rocket Lab’s bargaining position against SpaceX before Neutron has demonstrated reliability. The backlog cushions near-term demand concerns, but does not establish conversion timing or attractive margins.

The Iridium transaction adds a separate regulatory path risk: a challenge to the target’s competitive conduct could delay closing or dilute the strategic value Rocket Lab assigns to owning a network. It may also keep Iridium shares headline-sensitive; AST SpaceMobile could see an indirect opening if Iridium’s ability to contest rival services is constrained, though the letter alone does not establish that outcome.

Near term, the sharp selloff may already price in some disappointment, so chasing a short after the gap is unattractive. Over 1–3 months, watch for concrete tank remediation, revised launch milestones, and whether the FCC initiates substantive review. Over 6–18 months, the thesis turns on Neutron execution and backlog conversion. The contrarian point: Space Systems demand makes Rocket Lab more than a launch-delay story, but that diversification does not neutralize valuation risk while profitability remains distant. Reassess if management demonstrates on-schedule hardware milestones, segment growth converts into cash generation, or the FCC clears the acquisition without material conditions.

Key Decisions for Investors

• Do not buy the post-drop solely on the claim that the decline is excessive. Keep RKLB on an event-driven watchlist until the company provides verifiable tank remediation milestones and a credible Neutron schedule; failure to do so supports further multiple compression.
• For a relative-value expression, consider a modest, beta-aware short RKLB / long ITA pair rather than an outright short after the sharp decline. Revisit or exit if Neutron milestones recover credibility or Space Systems growth and cash conversion materially reduce dependence on the launch ramp.
• Track the FCC docket and transaction timeline as separate catalysts for RKLB and IRDM. A formal, extended review is a negative for the acquisition thesis; do not assume the Ligado filing itself changes AST SpaceMobile’s competitive position.
• Before adding exposure, verify backlog conversion cadence, Space Systems margins/cash flow, revised Neutron development costs, and the acquisition’s regulatory conditions; these are the missing data that determine whether current growth expectations are financeable.